68

Chemclin Diagnostics Co. Ltd. A

688468 · SHG · Healthcare / Diagnostics & Research

5.71CNY-0.11 (-1.89%)

Price History

Full chart

Market Stats

Previous Close5.82
Open5.83
Day Range5.69 – 5.88
52-Week Range5.50 – 8.55
Volume3.46M
Market Cap2.68B
P/E (TTM)74.33
Forward P/E0.00
EPS0.09
Dividend Yield0.00%
Beta0.08
50-Day Avg6.25
200-Day Avg6.94

About

Chemclin Diagnostics Co., Ltd. engages in the research, development, production, and sale of clinical immuno chemiluminescence diagnostic reagents and instruments in China. The company offers the LiCA series of diagnostic reagents, which is based on photo-induced chemiluminescence; the Chemclin series of diagnostic reagents and instruments, which is based on enzyme-catalyzed chemiluminescence; and routine clinical chemistry diagnostic reagents. Its products are used for the detection of biomarkers for infectious diseases, such as hepatitis B, hepatitis C, HIV, syphilis, hepatitis A, and hepatitis E, etc., as well as of tumor markers, thyroid hormones, reproductive endocrine hormones, cardiac markers, and inflammation. The company serves large and medium-sized hospitals, health check-up centers, emergency rooms, clinical laboratories, emergency departments, chest pain centers, and community centers. Chemclin Diagnostics Co., Ltd. was founded in 2005 and is headquartered in Beijing, China.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEOMr. Lin Li
  • Employees573
  • HeadquartersIncubation Bldg, Beijing, China, 100094, China
  • Websitehttps://www.chemclin.com

Leadership

  • Mr. Lin LiChairman & GM · b. 1962
  • Ms. Yanling HuangCFO, Secretary & Director · b. 1975
  • Mr. Zheng Ming HuangDeputy GM & Director · b. 1970
  • Li JinAccounting Supervisor
  • Mr. Zifu LianCore Technical Personnel · b. 1968
  • Ms. Yu Hui LiuCore Technical Personnel · b. 1971

Financials

Income Statement

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue318.60M366.06M454.67M418.20M470.77M465.27M445.34M436.29M332.68M
Growth (%)-+14.89%+24.21%-8.02%+12.57%-1.17%-4.28%-2.03%-23.75%
Cost of Revenue90.87M101.96M113.12M117.25M119.84M121.11M110.56M113.12M111.52M
Gross Profit227.73M264.10M341.55M300.95M350.94M344.16M334.78M323.17M221.16M
Gross Margin71.48%72.15%75.12%71.96%74.55%73.97%75.17%74.07%66.48%
Operating Expense647.98M676.50M181.82M164.10M188.36M173.87M168.50M188.43M170.84M
Operating Income-420.25M-412.41M159.73M136.85M162.58M170.29M166.29M134.74M50.32M
Operating Margin-131.90%-112.66%35.13%32.72%34.53%36.60%37.34%30.88%15.13%
EBITDA-382.48M-374.24M201.09M177.70M205.76M217.97M203.90M189.30M50.32M
EBITDA Margin-120.05%-102.23%44.23%42.49%43.71%46.85%45.78%43.39%15.13%
Net Income-435.23M-424.25M140.59M117.02M142.76M152.63M147.37M127.07M44.41M
Net Income Margin-136.61%-115.90%30.92%27.98%30.32%32.80%33.09%29.13%13.35%
R&D32.24M50.92M56.45M56.42M67.32M68.89M65.77M75.82M73.31M
R&D as % of Total Revenue10.12%13.91%12.42%13.49%14.30%14.81%14.77%17.38%22.04%
Interest Expense41.82K47.62K74.02K85.01K789.36K601.99K618.99K5.33M6.41M
Interest Expense % of Total Revenue0.01%0.01%0.02%0.02%0.17%0.13%0.14%1.22%1.93%

Balance Sheet

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets713.24M856.25M993.39M1.01B1.43B1.59B1.82B1.83B1.76B
Total Liabilities66.15M80.87M126.42M119.46M152.23M210.59M431.76M415.85M350.05M
Total Equity647.08M775.38M866.97M887.36M1.28B1.38B1.39B1.42B1.41B
Cash159.87M77.21M103.16M224.82M311.63M342.14M448.66M400.25M105.92M
Total Debt---10.20M24.60M12.47M234.61M224.32M-
Net Debt-159.87M-77.21M-103.16M-214.62M-287.03M-329.67M-214.05M-175.93M54.27M

Cash Flow

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow133.46M147.68M201.27M151.95M188.86M244.56M173.05M167.95M93.90M
Investing Cash Flow-61.35M-263.09M-130.79M-22.21M-310.54M-114.50M-307.68M-134.06M-
Financing Cash Flow32.76M32.53M-44.61M-111.19M242.00M-79.95M44.01M-87.93M-
Capital Expenditure59.43M48.51M55.24M83.31M72.55M125.28M301.37M107.49M69.88M
Free Cash Flow74.03M99.17M146.03M68.65M116.31M119.28M-128.32M60.46M24.01M
Dividends Paid--41.61M100.00M-68.17M139.15M53.28M54.79M
FCF to OCF55.47%67.15%72.55%45.18%61.59%48.77%-74.15%36.00%25.57%
Dividend Paid to FCF--28.49%145.67%-57.15%-108.44%88.13%228.16%

Earnings

Report DateJun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023
EPS Estimate--------
EPS Actual0.080.090.090.100.080.120.090.09
Surprise--------
Timing--------

Key Statistics & Ratios

Market Cap2.68B
Enterprise Value2.48B
Trailing P/E74.33
Forward P/E0.00
Price / Sales8.32
Price / Book1.85
EPS0.09
Book Value3.62
Revenue (TTM)322.53M
Gross Profit (TTM)195.73M
EBITDA61.39M
Profit Margin10.89%
Operating Margin2.01%
Return on Equity2.49%
Return on Assets0.62%
Shares Outstanding401.11M
Shares Float230.77M
Beta0.08
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20251×
0.13Jun 13, 2025
20241×
0.13Jun 14, 2024
20231×
0.35Jun 2, 2023
20221×
0.17Jun 8, 2022